MX2023003942A - Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r. - Google Patents

Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.

Info

Publication number
MX2023003942A
MX2023003942A MX2023003942A MX2023003942A MX2023003942A MX 2023003942 A MX2023003942 A MX 2023003942A MX 2023003942 A MX2023003942 A MX 2023003942A MX 2023003942 A MX2023003942 A MX 2023003942A MX 2023003942 A MX2023003942 A MX 2023003942A
Authority
MX
Mexico
Prior art keywords
methods
antagonist
asthma
administration
treatment
Prior art date
Application number
MX2023003942A
Other languages
English (en)
Spanish (es)
Inventor
Bolanle Akinlade
Nikhil Amin
Marcella Ruddy
Christine Xu
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2023003942A publication Critical patent/MX2023003942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023003942A 2020-10-05 2021-10-04 Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r. MX2023003942A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063087668P 2020-10-05 2020-10-05
US202063109719P 2020-11-04 2020-11-04
US202163144048P 2021-02-01 2021-02-01
US202163157922P 2021-03-08 2021-03-08
EP21315151 2021-08-31
PCT/US2021/053328 WO2022076289A1 (en) 2020-10-05 2021-10-04 Methods for treating asthma in pediatric subjects by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
MX2023003942A true MX2023003942A (es) 2023-06-02

Family

ID=78414079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003942A MX2023003942A (es) 2020-10-05 2021-10-04 Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.

Country Status (9)

Country Link
US (1) US20220169739A1 (enExample)
EP (1) EP4225436A1 (enExample)
JP (1) JP2023544406A (enExample)
KR (1) KR20230082650A (enExample)
AU (1) AU2021357078A1 (enExample)
BR (1) BR112023004020A2 (enExample)
CA (1) CA3194111A1 (enExample)
MX (1) MX2023003942A (enExample)
WO (1) WO2022076289A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
WO2024011251A1 (en) * 2022-07-08 2024-01-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
WO2025026821A1 (en) * 2023-07-28 2025-02-06 Novartis Ag New uses of omalizumab
TW202620051A (zh) * 2024-09-18 2026-05-16 香港商香港康乃德生物醫藥有限公司 介白素-4受體α抗體的使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
US11034768B2 (en) * 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도

Also Published As

Publication number Publication date
AU2021357078A9 (en) 2025-04-10
JP2023544406A (ja) 2023-10-23
CA3194111A1 (en) 2022-04-14
US20220169739A1 (en) 2022-06-02
WO2022076289A1 (en) 2022-04-14
EP4225436A1 (en) 2023-08-16
KR20230082650A (ko) 2023-06-08
BR112023004020A2 (pt) 2023-04-25
AU2021357078A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2022001247A (es) Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
MX2022001030A (es) Metodos para tratar alergia y mejorar la inmunoterapia especifica de alergenos mediante la administracion de un antagonista de il-4r.
BR112015013095A8 (pt) Cânula nasal para distribuição de gás terapêutico a um paciente
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX2021013327A (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
MX385543B (es) Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b.
BR112018013245A2 (pt) método e aparelho para administração óxido nítrico com drogas suplementares
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112022015363A2 (pt) Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
MX2018005625A (es) Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales.
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.